Atopic Dermatitis Summit: Perspectives on a Global Burden of Disease

The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control.  There are several new targeted therapeutics with novel mechanisms of action, as well as existing therapies being investigated for treatment in additional age indications, being added to the treatment toolkit for moderate-to-severe atopic dermatitis around the globe, including but not limited to the United States, Canada, European Union, Japan, and China. It is imperative that clinicians are aware of the need for these newer targeted therapies, how to prescribe them appropriately for optimized treatment regimens and patient outcomes, and how to address any region-specific challenges with patient care.

Target Audience

This educational activity is designed for a global audience of physicians, nurses, pharmacists, and other allied health providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.

Learning Objectives

  • Review clinical features of moderate-to-severe atopic dermatitis
  • Identify tools for assessing atopic dermatitis severity
  • Summarize the efficacy and safety of current and emerging targeted therapies for treatment of moderate-to-severe AD
  • Discuss individualized treatment plans for pediatric and adult patients with moderate-to-severe AD that promote long-term disease management and improved quality of life
  • Recognize strategies for patient-clinician communication that will aid shared decision making in the treatment of AD
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Course opens: 
Course expires: 
  • AD Across the Globe: North America
  • AD Across the Globe: Europe and the
  • AD Across the Globe: Japan and China
  • Interactive Panel Discussion

Prof. Thomas Bieber, MD, PhD, MDRA, Prof. h.c.
Dept. of Dermatology and Allergy, University Hospital, Bonn, Germany
Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland


Kenji Kabashima, MD, PhD
Kyoto University Graduate School of Medicine
Department of Dermatology, Japan
SRIS/SIgN, A*Star, Singapore


Jonathan I. Silverberg, M.D., Ph.D., M.P.H.
Professor, Department of Dermatology
Director, Clinical Research
Director, Patch Testing
The George Washington University School of Medicine and Health Sciences
Washington, DC USA

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and LiVDerm.  Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Term Offering

This activity was released on March 31, 2023 and is valid for one year. Requests for credit must be made no later than March 31, 2024.


Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or


Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the activity in person, complete the posttest with 70% or better, and complete the program evaluation.


Fee Information & Refund/Cancellation Policy

There is $0 fee for this educational activity.


Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter

Reported Financial Relationship

Prof. Thomas Bieber, MD, PhD, MDRA, Prof. h.c

Consulting Fee (e.g., Advisory Board): AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L´Oréal, MSD, Medac, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB, Union Therapeutics.

Kenji Kabashima, MD, PhD

Nothing to disclose

Jonathan I. Silverberg, M.D., Ph.D., M.P.H.

Consulting Fee (e.g., Advisory Board): Abbvie, Alamar, Aldena, Amgen, AObiome, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate

Contracted Research: Galderma, Incyte, Pfizer

Speakers' Bureau: Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager

Reported Financial Relationship

Lindsay Borvansky

Nothing to disclose

Andrea Funk

Nothing to disclose

Liddy Knight

Nothing to disclose

Ashley Cann

Nothing to disclose

Lauren Sinclair

Nothing to disclose

Kelly Pechous

Nothing to disclose

Deborah Sharkey

Nothing to disclose


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and LiVDerm do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Available Credit

  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

System Requirements

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)

Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome

For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14

Mozilla Firefox, Apple Safari, Google Chrome

For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)